|
Source – Medscape Medical News - The FDA has approved an intravenous route of administration for pegaspargase injection (Oncaspar, made by Enzon Pharmaceuticals, Inc.). The pediatric product was previously approved for delivery via intramuscular injection, which is often painful to patients.
Pegaspargase is indicated for use in conjunction with other chemotherapeutics for the treatment of acute lymphoblastic lymphoma in
patients who are hypersensitive or allergic to native forms of L-asparaginase.
Compared with native forms, pegaspargase is associated with decreased immunogenicity and an increased half-life that allows for its
bimonthly rather than biweekly administration.
This product is not licensed in the United Kingdom.
For more information go to: http://www.medscape.com/viewarticle/517336
Prepared by Susan Wileman Medicines Information Technician
Date of Preparation: 18th November 2005
|
